Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism CCL2 inhibitors(C-C motif chemokine 2 inhibitors), CCL5 inhibitors(C-C motif chemokine 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Poisoning | Phase 1 | - | - | |
Brain Injuries, Traumatic | Preclinical | US | - | 31 Oct 2019 |
Drug intoxication | Preclinical | US | 22 Oct 2019 | |
Cognition Disorders | Preclinical | US | - | 29 Sep 2019 |
Alzheimer Disease | Preclinical | US | - | 21 Sep 2019 |
Multiple Sclerosis | Preclinical | US | - | 20 Sep 2019 |
Phase 1 | 40 | Placebo (Placebo) | kjiggvphkw(vhaccjfwip) = coqtddyehj chkugmeene (jcdmzgsmmh, tdjidqmgtq - rijqkzzqzk) View more | - | 30 Dec 2022 | ||
(Dose 1) | kjiggvphkw(vhaccjfwip) = eertfasxgl chkugmeene (jcdmzgsmmh, wgunzcwrmm - vuqwhwenbs) View more |